BiologicalDrug

Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 clinical trials

studies test it: 5
open now: 3
in phase 3: 0
first study started: 2017

Keep track of what changes. Save the Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

MB-CART19.1: 5
CD19-targeting CAR T cells: 3
Anti-CD19 CAR T cells: 3

Studies by the year they started

5 studies that test it; most in 2024 (2)

Studies that test Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1, by start year
Year	Studies
2017	1
2018	1
2024	2
2026	1

By phase

A phase 1/2 study counts in both.

Phase 1: 3
Phase 2: 3
No phase: 1

What it is tested for

Each study’s main condition, where its own words name it.

Melanoma: 1
Lupus Erythematosus, Systemic: 1
Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1

Who runs them

Industry 3 · Other 2

Miltenyi Biomedicine GmbH (3) · Hospital Universitario Dr. Jose E. Gonzalez (1) · Shanghai Children's Medical Center (1)

Often tested with

Tested in the same studies.

Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1 (1) · Zamtocabtagene autoleucel (1)

Studies

Open first, then newest update. How each study uses Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 is read from its arms, and is right about nine times in ten.